Roundhill Investments - GLP-1 & Weight Loss ETF
$28.89−0.47 (−1.60%)
- 0.59%
- $55M
- +3.7%
- 1.40%
- 0M sh
- $29.56
- low $27.34high $37.15
The ETF.net OZEM Grade
C
Score 43 out of 100
- 7 of 9
Score 43 of 100 falls in the C band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.
Cost
The fund’s net expense ratio, ranked against its category.C41 out of 100Rank 5 of 9Mission
Whether the fund did what it promised, tested against its stated mandate.B67 out of 100Rank 4 of 6Risk
How the fund held up when markets fell: downside volatility, drawdowns and tail loss.F20 out of 100Rank 8 of 9Tradability
How easy the fund is to trade: daily volume, and how far its price strays from net asset value.D29 out of 100Rank 7 of 9Holdings
How concentrated the fund is, and how complete and current its disclosed holdings are.C52 out of 100Rank 6 of 9Durability
Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.C42 out of 100Rank 7 of 9
Our read on OZEM
CThe whole weight-loss trade in one ticker: roughly 30 stocks covering the drugmakers behind GLP-1 treatments plus the companies expected to benefit as use widens. Broad pharma funds bury this theme. OZEM is built entirely around it.
The Fund seeks capital appreciation by providing exposure to companies developing pharmaceutical drugs for weight loss and anti-obesity, including GLP-1 treatments, as well as companies expected to benefit from their wider use.
Why people hold it
- The mandate is explicit: companies developing weight-loss and anti-obesity drugs, including GLP-1s, plus firms expected to benefit from wider use. No hedging into general pharma.
- A roughly 30-stock lineup means the theme actually drives the fund, rather than sitting as a small sleeve inside a diversified pharma basket.
- At 0.59%, the fee sits in the same neighborhood as established pharma funds like PJP (0.57%) and FTXH (0.60%), despite the narrower, more specialized mandate.
Worth knowing
- Broad pharma alternatives are cheaper: XPH at 0.35% and PPH at 0.36%. The theme focus here carries a price.
- Thinly traded with a modest asset base, so spreads can be wide. Limit orders are the standard tool for funds in this range.
- Launched in 2024, so the history is short, and a 30-stock single-theme basket swings on trial results and regulatory news at a handful of companies.
OZEM Holdings
- Stocks
- 27
- 67%
- LLY
Sectors
- Health Care100.0%
Geography
- United States43.30%
- China18.64%
- Denmark17.42%
- Japan6.10%
- South Korea4.44%
- United Kingdom3.92%
- Switzerland3.31%
- Hong Kong2.87%
Developed 59% · Emerging 41%
OZEM Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Not enough history yet.Not enough history yet.Not enough history yet.
OZEM$10,373
Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | OZEM |
|---|---|
| Year to date | −14.1% |
| 1 month | −5.7% |
| 3 months | −11.4% |
| 1 year | +3.7% |
| 3 years | — |
| 5 years | — |
| 10 years | — |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | OZEM |
|---|---|---|
| 2026 YTD | −14.1% | |
| 2025 | +41.9% | |
| 2024 | −3.8% |
OZEM in the news
OZEM Dividends
- 1.40%
- $0.41
- $0.41 per share
- Irregular
Distribution history
OZEM Risk
- 20.1%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.36
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −28.6%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.47
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
OZEM Cost
0.59%
OZEM0.59%
- The middle half of Pharma & Therapeutics funds
- Median 0.58%
5 of the 9 Pharma & Therapeutics funds charge less.
Other funds in Pharma & Therapeutics
- BPJPInvesco Pharmaceuticals ETFExpense ratio 0.58%1 year return +34.5%
- BPBPHPortfolio Building Block World Pharma and Biotech Index ETFExpense ratio 0.13%1 year return —
- BFTXHFirst Trust Nasdaq Pharmaceuticals ETFExpense ratio 0.60%1 year return +43.8%
- CTHNRAmplify Weight Loss Drug & Treatment ETFExpense ratio 0.59%1 year return +4.1%
- FPSILAdvisorShares Psychedelics ETFExpense ratio 1.84%1 year return +20.4%